Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib versus neratinib + capecitabine versus lapatinib + capecitabine in HER2-positive advanced or metastatic breast cancer
2008-001662-85Phase 2Completed
- Sponsor
- Wyeth
- Start
- Sep 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Nonhematologic neoplasms and breast cancer comparing Neratinib monotherapy, Neratinib + capecitabine and Lapatinib + capecitabine (3 arms). Primary endpoints: Safety and tolerability, Maximum tolerated dose and 1 more. Started Sep 2008; status: completed.
02
Drugs
neratinibcapecitabinelapatinib
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on 2008-001662-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001662-85.